Journal article
MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma
Abstract
BACKGROUND: In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes. MG98 was designed to inhibit DNA methyltransferases enzyme 1 production.
METHODS: This multicenter study explored two schedules of MG98 with Interferon-α-2β to identify schedule and dose for patients with metastatic RCC.
Authors
Amato RJ; Stephenson J; Hotte S; Nemunaitis J; Bélanger K; Reid G; Martell RE
Journal
Cancer Investigation, Vol. 30, No. 5, pp. 415–421
Publisher
Taylor & Francis
Publication Date
May 23, 2012
DOI
10.3109/07357907.2012.675381
ISSN
0735-7907